Acellular pertussis vaccine

BIOLOGICAL2 trials

Sponsors

Novartis Vaccines, Adjuvance Technologies, Inc.

Conditions

DiphtheriaLockjawPertussisTetanusWhooping Cough

Phase 1

Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years

CompletedNCT01529645

Novartis VaccinesDiphtheria, Lockjaw, Pertussis +2

Start: 2012-03-31End: 2013-07-31Updated: 2016-04-04

Pertussis Acellular Vaccine Adjuvanted With TQL1055

TerminatedNCT04793620

Adjuvance Technologies, Inc.Pertussis

Start: 2021-04-06End: 2022-02-14Updated: 2022-11-01

Related Papers

A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults

Human Vaccines & Immunotherapeutics2017-11-2713 citations